Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties

The insulin-like growth factor (IGF) axis has been implicated in the progression of malignant disease and identified as a clinically important therapeutic target. Several IGF-1 receptor (IGF-1R) targeting drugs including humanized monoclonal antibodies have advanced to phase II/III clinical trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaniotis, George, Moffett, Serge, Sulea, Traian, Wang, Ni, Elahi, S. Mehdy, Lessard, Etienne, Baardsnes, Jason, Perrino, Stephanie, Durocher, Yves, Frystyk, Jan, Massie, Bernard, Brodt, Pnina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255772/
https://www.ncbi.nlm.nih.gov/pubmed/30478273
http://dx.doi.org/10.1038/s41598-018-35407-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255772/
https://www.ncbi.nlm.nih.gov/pubmed/30478273
http://dx.doi.org/10.1038/s41598-018-35407-2

Ejemplares similares